Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Cagrilintide/semaglutide

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglu

Novo Nordisk · Phase 2 · Completed · Enrollment 626

NCT06131372

EudraCT 2023-505857-42

No selected arm has a reported week for this endpoint.

    A solid line connects the weeks the source reports.